TY - JOUR
T1 - Baseline serum Mac-2 binding protein glycosylation isomer as a predictor of hepatocellular carcinoma in chronic hepatitis B patients
T2 - a systematic review and meta-analysis
AU - Witarto, Andro Pramana
AU - Witarto, Bendix Samarta
AU - Pramudito, Shidi Laras
AU - Putra, Achmad Januar Er
AU - Nurhadi, Grace Manuela
AU - Maimunah, Ummi
N1 - Publisher Copyright:
© 2022 Hellenic Society of Gastroenterology.
PY - 2022/11/19
Y1 - 2022/11/19
N2 - Background A minimally invasive tool to promptly predict hepatocellular carcinoma (HCC) in chronic hepatitis B (CHB) is currently needed. In this study, we aimed via a meta-analysis to identify the serum Mac-2 binding protein glycosylation isomer (M2BPGi) as a novel glycoprotein-based liver fibrosis marker for predicting HCC in CHB patients. Methods We conducted a systematic search on PubMed, Scopus, ProQuest, Wiley Online Library, and CINAHL Plus (via EBSCOhost). The articles were screened based on several eligibility criteria and were further assessed for study qualities using the Newcastle-Ottawa Scale. The outcomes were presented as standard mean difference (SMD), hazard ratio (HR), and predictive accuracy parameters of a baseline cutoff index (COI) for serum M2BPGi. Results Fourteen studies involving 5918 CHB patients were included in this systematic review and meta-analysis. Baseline COI serum M2BPGi was significantly higher in CHB patients who developed HCC than in those who did not (SMD 1.32, 95% confidence interval [CI] 0.91-1.72). A significant HCC risk prediction was also observed (multivariate HR 1.18, 95%CI 1.05-1.32). Baseline COI serum M2BPGi could predict HCC with a pooled sensitivity of 74% (95%CI 50-89%), specificity of 80% (95%CI 65-90%), and area under the summary receiver operating characteristic curve of 0.84 (95%CI 0.81-0.87). Conclusion High baseline COI serum M2BPGi may predict the development of HCC in CHB patients with moderate-to-high accuracy.
AB - Background A minimally invasive tool to promptly predict hepatocellular carcinoma (HCC) in chronic hepatitis B (CHB) is currently needed. In this study, we aimed via a meta-analysis to identify the serum Mac-2 binding protein glycosylation isomer (M2BPGi) as a novel glycoprotein-based liver fibrosis marker for predicting HCC in CHB patients. Methods We conducted a systematic search on PubMed, Scopus, ProQuest, Wiley Online Library, and CINAHL Plus (via EBSCOhost). The articles were screened based on several eligibility criteria and were further assessed for study qualities using the Newcastle-Ottawa Scale. The outcomes were presented as standard mean difference (SMD), hazard ratio (HR), and predictive accuracy parameters of a baseline cutoff index (COI) for serum M2BPGi. Results Fourteen studies involving 5918 CHB patients were included in this systematic review and meta-analysis. Baseline COI serum M2BPGi was significantly higher in CHB patients who developed HCC than in those who did not (SMD 1.32, 95% confidence interval [CI] 0.91-1.72). A significant HCC risk prediction was also observed (multivariate HR 1.18, 95%CI 1.05-1.32). Baseline COI serum M2BPGi could predict HCC with a pooled sensitivity of 74% (95%CI 50-89%), specificity of 80% (95%CI 65-90%), and area under the summary receiver operating characteristic curve of 0.84 (95%CI 0.81-0.87). Conclusion High baseline COI serum M2BPGi may predict the development of HCC in CHB patients with moderate-to-high accuracy.
KW - Biomarker
KW - Mac-2 binding protein glycosylation isomer
KW - Wisteria floribunda agglutinin-positive Mac-2 binding protein
KW - chronic hepatitis B
KW - hepatocellular carcinoma
UR - http://www.scopus.com/inward/record.url?scp=85142190097&partnerID=8YFLogxK
U2 - 10.20524/aog.2022.0751
DO - 10.20524/aog.2022.0751
M3 - Article
AN - SCOPUS:85142190097
SN - 1108-7471
VL - 35
SP - 627
EP - 639
JO - Annals of Gastroenterology
JF - Annals of Gastroenterology
IS - 6
ER -